Welcome to our dedicated page for TANDEM DIABETES CARE SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TANDEM DIABETES CARE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TANDEM DIABETES CARE's regulatory disclosures and financial reporting.
Voya Financial, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Tandem Diabetes Care, Inc. Voya reports beneficial ownership of 149,088 shares of Tandem’s common stock, representing 0.2% of the outstanding class.
Voya states it has sole voting power and sole dispositive power over all 149,088 shares, with no shared voting or dispositive power. The filing notes that this ownership represents 5 percent or less of the class and is reported by Voya as the ultimate parent of certain wholly owned subsidiaries listed on an exhibit.
Tandem Diabetes Care EVP & Chief Operating Officer Jean-Claude Kyrillos reported equity compensation activity. On July 15, 2026, 3,636 restricted stock units converted into common stock, bringing his direct holdings to 31,741 shares. To satisfy tax withholding on the vesting, the company withheld 1,926 shares at $15.28 per share; no shares were sold in the market. After this vesting, 14,545 RSUs from a July 2024 grant under the 2023 Long-Term Incentive Plan remain outstanding.
Tandem Diabetes Care submitted a Rule 144 notice to sell 361 shares of its common stock represented by Restricted Stock Units, with an issuer-designated sale method dated 06/15/2026.
Separately, the filing discloses a 10b5-1 sale by Mark Novara of 266 shares on 05/19/2026, reported in the "Securities Sold During The Past 3 Months" section. The filing lists broker details as Morgan Stanley Smith Barney LLC.
Tandem Diabetes Care executive Elizabeth Anne Gasser reported gift transfers of company common stock. On June 2, she disposed of a total of 14,320 shares as bona fide gifts, including a transfer from her direct holdings to The Gasser Family Trust dated September 1, 2011 for no consideration. After these transactions, the trust holds 33,109 shares indirectly with Gasser as co-trustee, and her reported direct common stock holdings are 0 shares. These are non-market, estate-planning type movements rather than open-market sales.
Sheridan John F reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care reported that President and CEO John F. Sheridan received a grant of 191,103 restricted stock units (RSUs). Each RSU represents the right to receive one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan.
One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, encouraging longer-term alignment between the CEO and shareholders.
Gasser Elizabeth Anne reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care Inc. reported that EVP and Chief Strategy Officer Elizabeth Anne Gasser received a grant of 29,136 restricted stock units (RSUs). Each RSU represents a contingent right to one share of common stock or cash, at the company’s discretion, under the 2023 Long-Term Incentive Plan.
All 29,136 RSUs are held directly and bring her reported RSU holdings in this award to 29,136 units. One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, subject to the plan’s terms. This is a compensation-related equity award, not an open-market purchase or sale.
Vosseller Leigh reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care executive vice president and chief financial officer Leigh Vosseller received a grant of 62,657 restricted stock units (RSUs) under the company’s 2023 Long-Term Incentive Plan. Each RSU represents a contingent right to receive one share of common stock or cash at the company’s discretion.
One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, subject to plan terms and continued eligibility. This is a stock-based compensation award, not an open-market share purchase or sale.
Kyrillos Jean-Claude reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care executive vice president and chief operating officer Jean-Claude Kyrillos received a grant of 29,136 restricted stock units (RSUs). Each RSU represents a contingent right to one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan.
One-third of these RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, subject to plan terms. Following this grant, Kyrillos directly holds 29,136 RSUs linked to common stock.
Morrison Susan reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care executive Susan Morrison received a grant of 29,136 restricted stock units as part of equity compensation. Each RSU represents a right to receive one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan. One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, contingent on plan terms and continued service. Following this award, Morrison holds 29,136 RSUs directly.
Carpenter Rick reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care EVP & Chief Technology Officer Rick Carpenter received a grant of 26,003 restricted stock units (RSUs). Each RSU represents a right to receive one share of common stock or cash, under the company’s 2023 Long-Term Incentive Plan. One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments thereafter, subject to plan terms and continued service.